Dr Reddy’s Laboratories will benefit from six months of market exclusivity for the first generic rival to Pfizer’s Hemabate carboprost tromethamine single-dose vials that the Indian firm has introduced upon approval in the US.
By securing final approval from the Food and Drug Administration for the 250µg/1ml vials as a competitive generic therapy (CGT),...



